Recently Viewed
Clear AllValue Research Rating
Quality Score 
0/0
Growth Score
0/0
Valuation Score
0/0
Momentum Score
0/0
Today’s Range
52 Week Range
Liquidity
Market cap
₹13,646 Cr
Revenue (TTM)
₹7,918 Cr
Net Profit (TTM)
₹433 Cr
ROE
14.3 %
ROCE
13.9 %
P/E Ratio
31.5
P/B Ratio
2.1
Industry P/E
46.99
EV/EBITDA
11.8
Div. Yield
0.6 %
Debt to Equity
0.4
Book Value
₹417.3
EPS
₹29
Face value
1
Shares outstanding
159,281,139
CFO
₹11,660.93 Cr
EBITDA
₹12,801.07 Cr
Net Profit
₹4,681.62 Cr
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Jubilant Pharmova
| -20.2 | -4.8 | -18.1 | 0.0 | 39.8 | 3.0 | 17.3 |
|
BSE Healthcare
| -1.7 | -1.1 | -1.9 | 7.5 | 25.6 | 15.6 | 10.7 |
|
Company
|
2025
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
|---|---|---|---|---|---|---|---|
|
Jubilant Pharmova
| -0.6 | 90.5 | 45.6 | -36.1 | -31.1 | 58.6 | -24.6 |
|
BSE Small Cap
| -6.6 | 29.0 | 47.5 | -1.8 | 62.8 | 32.1 | -6.8 |
|
BSE Healthcare
| -3.3 | 43.1 | 37.0 | -12.1 | 20.9 | 61.4 | -3.5 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price (₹) | Market Cap (₹ Cr) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Jubilant Pharmova
|
856.6 | 13,645.6 | 7,918.4 | 429.9 | 10.7 | 7.2 | 31.5 | 2.1 |
| 2,257.8 | 18,500.8 | 1,215.1 | 284.8 | 28.7 | 21.1 | 64.5 | 12.2 | |
| 676.3 | 13,282.8 | 7,266.8 | 627.5 | 11.9 | 12.6 | 21.1 | 2.4 | |
| 306.3 | 11,719.9 | 2,051.5 | 180.5 | 11.6 | 7.7 | 58.1 | 3.1 | |
| 587.2 | 14,551.9 | 5,092.5 | 545.5 | 15.9 | 14.1 | 26.7 | 3.5 | |
| 957.9 | 17,149.8 | 4,560.2 | 1,544.6 | 35.1 | 19.2 | 11 | 2.0 | |
| 1,471.6 | 16,867.1 | 1,419.3 | 20.1 | 8.4 | 0.5 | 839.1 | 2.9 | |
| 143.1 | 19,028.2 | 8,871.4 | -223.5 | 1.9 | -1.6 | -- | 2.4 | |
| 419.9 | 16,903.3 | 3,720.2 | 352.1 | 13.7 | 8.2 | 48 | 3.6 | |
| 1,215.6 | 19,800.5 | 3,151.0 | -10.0 | 8.4 | 2.5 | 900 | 4.3 |
Jubilant Pharmova Limited operates as an integrated pharmaceutical and life sciences company in India, the Americas, Europe, and internationally. It operates through six segments: Radiopharma, Allergy Immunotherapy, CDMO Sterile Injectables,... Generics, Contract Research Development & Manufacturing Organisation (CRDMO), and Proprietary Novel Drugs. The Radiopharma segment offers radiopharmaceuticals products, which are used in the diagnosis and treatment of various diseases, including pulmonary embolism, cancer, coronary artery disease, and others. The Allergy Immunotherapy segment provides specialised diagnostic devices for skin testing, as well as venom immunotherapy products. The CDMO Sterile Injectables segment offers contract manufacturing services for sterile fill and finish injectables, liquids, ointments, creams, and ampoules. The Generics segment engages in the development, manufacturing, distribution, sale, and marketing of solid dosage formulations for therapeutic areas comprising cardiovascular system, central nervous system, gastrointestinal, and multispecialty. The CRDMO segment offers drug discovery and development services and active pharmaceutical ingredients. The Proprietary Novel Drugs segment develops therapies in the areas of oncology and auto-immune diseases. The company was formerly known as Jubilant Life Sciences Limited and changed its name to Jubilant Pharmova Limited in February 2021. Jubilant Pharmova Limited was incorporated in 1978 and is based in Noida, India. Read more
Incorporated
1978
Chairman
Shyam S Bhartia
Managing Director
Priyavrat Bhartia
Group
Jubilant Bhartia
Headquarters
Gajraula, Uttar Pradesh
Website
Our rating system has guided millions of investors in the past 20 years.
The share price of Jubilant Pharmova Ltd is ₹856.60 (NSE) and ₹856.70 (BSE) as of 18-Mar-2026 IST. Jubilant Pharmova Ltd has given a return of 39.83% in the last 3 years.
The P/E ratio of Jubilant Pharmova Ltd is 31.54 times as on 18-Mar-2026, a 33 discount to its peers’ median range of 46.99 times.
The P/B ratio of Jubilant Pharmova Ltd is 2.05 times as on 18-Mar-2026, a 32 discount to its peers’ median range of 3.02 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2025
|
16.80
|
2.26
|
|
2024
|
116.50
|
1.66
|
|
2023
|
0.00
|
0.82
|
|
2022
|
14.91
|
1.16
|
|
2021
|
12.96
|
2.28
|
The 52-week high and low of Jubilant Pharmova Ltd are Rs 1,248.00 and Rs 786.05 as of 19-Mar-2026.
Jubilant Pharmova Ltd has a market capitalisation of ₹ 13,646 Cr as on 18-Mar-2026. As per SEBI classification, it is a Small Cap company.
Before investing in Jubilant Pharmova Ltd, assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
₹18.90
(
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.